tiprankstipranks
Advertisement
Advertisement
Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer
PremiumCompany AnnouncementsBlack Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer
4M ago
3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026
Premium
Market News
3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026
4M ago
Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
Premium
Ratings
Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
5M ago
Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
PremiumThe FlyBlack Diamond Therapeutics announces data from Phase 2 trial of silevertinib
5M ago
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
Premium
The Fly
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
6M ago
Black Diamond Therapeutics files $500M mixed securities shelf
Premium
The Fly
Black Diamond Therapeutics files $500M mixed securities shelf
6M ago
Black Diamond Therapeutics resumed with a Buy at Stifel
PremiumThe FlyBlack Diamond Therapeutics resumed with a Buy at Stifel
7M ago
Black Diamond Therapeutics initiated with a Buy at Freedom Capital
Premium
The Fly
Black Diamond Therapeutics initiated with a Buy at Freedom Capital
7M ago
Black Diamond, TransMedics, Duolingo, AT&T, Coherus: Trending by Analysts
Premium
Weekend Updates
Black Diamond, TransMedics, Duolingo, AT&T, Coherus: Trending by Analysts
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100